register

News & Trends - MedTech & Diagnostics

Ramsay collaborates with AOA on national orthopaedics project

Health Industry Hub | March 12, 2021 |

MedTech News: Ramsay Health Care is taking part in a national project that provides a structured way for patients to report information about their health outcomes.

Ramsay has agreed to participate in a Patient Reported Outcome Measures (PROMS) Project facilitated by the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). 

The AOANJRR recently completed a successful pilot project which tested the feasibility of collecting PROMs data in addition to the surgical procedure data already being collected.  

The study found gathering PROMs data had major benefits for both patients and the health care system. 

According to the AOANJRR “PROMs data allows both the patient and clinician to gain important insight into the individual health care experience and promotes shared decision making.” 

Following the pilot, the Australian Orthopaedics Association (AOA) has now secured government funding to implement PROMs collection nationally and permanently within its national joint replacement registry.  

Five Ramsay hospitals were involved in the pilot project. Kareena Private, St George Private, North Shore Private, Westmead Private and Greenslopes Private will all now transition across to the ongoing national PROMs project. Other Ramsay sites and surgeons who offer joint replacement surgery will also now be encouraged to join the project. 

Patients will be surveyed on outcomes including pain, function and quality of life. Ramsay Health Care supports the collection of patient-reported outcomes as an important part of any patient journey.  

Surgeons may choose whether to participate in the study and should discuss the project with patients when booking joint replacement procedures.  

Hospitals may choose to support this process and discussions should occur at a local level around the operational aspects of the project.  

The AOA project team will be responsible for any patient follow-up and will play an active role in supporting hospitals with implementation of the project.  

Patient PROMS data is collected via an automated electronic data capture platform known as RAPID (Real time Automated Platform for Integrated Data capture). The RAPID system allows patients to be registered in the system prior to their joint replacement. Patients provide consent to participate and subsequently report on outcomes relating to their health via an online platform. Patients receive SMS or email reminders to complete the PROMS surveys at the required timepoints.  

Stakeholders including patients, surgeons and hospitals will have access to their own real-time data (via dashboards) in comparison to national averages. 


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.